Jessica J Bartoszko1, Isabella F McNamara1, Oguz A Z Aras2, Danielle A Hylton1, Yuan B Zhang1, Danya Malhotra3, Sarah L Hyett1, Rita E Morassut1, Paulina Rudziak4, Mark Loeb5. 1. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario L8N 3Z5, Canada. 2. University of Toronto, Toronto, Ontario M5S 1A1, Canada. 3. McMaster University, Hamilton, Ontario L8S 4L8, Canada. 4. Hamilton Health Sciences, Hamilton, Ontario L8N 3Z5, Canada. 5. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario L8N 3Z5, Canada; Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4L8, Canada; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8N 3Z5, Canada. Electronic address: loebm@mcmaster.ca.
Abstract
INTRODUCTION: Vaccination against influenza on an annual basis is widely recommended, yet recent studies suggest consecutive vaccination may reduce vaccine effectiveness (VE). PURPOSE: To assess whether when examining the entirety of existing data consecutive influenza vaccination reduces VE compared to current season influenza vaccination. DATA SOURCES: MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to April 26, 2017; citations of included studies. STUDY SELECTION: Randomized, controlled trials (RCTs) and observational studies of children, adults and/or the elderly that reported laboratory-confirmed influenza infection over 2 or more consecutive influenza seasons were eligible. DATA EXTRACTION: Data related to study characteristics, participant demographics, cases of influenza infection by vaccination group and risk of bias assessment was extracted in duplicate. DATA SYNTHESIS: Five RCTs involving 11,987 participants did not show a significant reduction in VE when participants vaccinated in two consecutive seasons (VE 71%, 95% CI 62-78%) were compared to those vaccinated in the current season (VE 58%, 95% CI 48-66%) (odds ratio [OR] 0.88, 95% CI 0.62-1.26, p = 0.49, I2 = 39%). Twenty-eight observational studies involving 28,627 participants also did not show a reduction (VE for two consecutive seasons 41%, 95% CI 30-51% compared to VE for current season 47%, 95% CI 39-54%; OR 1.14, 95% CI 0.98-1.32, p = 0.09, I2 = 63%). Results from subgroup analyses by influenza type/subtype, vaccine type, age, vaccine match and co-morbidity support these findings; however, dose-response results were inconsistent. Certainty in the evidence was assessed to be very low due to unexplained heterogeneity and imprecision. LIMITATIONS: The inclusion of studies with relatively small sample sizes and low event rates contributed to the imprecision of summary VE and OR estimates, which were based on unadjusted data. CONCLUSION: Available evidence does not support a reduction in VE with consecutive influenza vaccination, but the possibility of reduced effectiveness cannot be ruled out due to very low certainty in this evidence. FUNDING SOURCE: CIHR Foundation Grant (PROSPERO: CRD42017059893).
INTRODUCTION: Vaccination against influenza on an annual basis is widely recommended, yet recent studies suggest consecutive vaccination may reduce vaccine effectiveness (VE). PURPOSE: To assess whether when examining the entirety of existing data consecutive influenza vaccination reduces VE compared to current season influenza vaccination. DATA SOURCES: MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to April 26, 2017; citations of included studies. STUDY SELECTION: Randomized, controlled trials (RCTs) and observational studies of children, adults and/or the elderly that reported laboratory-confirmed influenza infection over 2 or more consecutive influenza seasons were eligible. DATA EXTRACTION: Data related to study characteristics, participant demographics, cases of influenza infection by vaccination group and risk of bias assessment was extracted in duplicate. DATA SYNTHESIS: Five RCTs involving 11,987 participants did not show a significant reduction in VE when participants vaccinated in two consecutive seasons (VE 71%, 95% CI 62-78%) were compared to those vaccinated in the current season (VE 58%, 95% CI 48-66%) (odds ratio [OR] 0.88, 95% CI 0.62-1.26, p = 0.49, I2 = 39%). Twenty-eight observational studies involving 28,627 participants also did not show a reduction (VE for two consecutive seasons 41%, 95% CI 30-51% compared to VE for current season 47%, 95% CI 39-54%; OR 1.14, 95% CI 0.98-1.32, p = 0.09, I2 = 63%). Results from subgroup analyses by influenza type/subtype, vaccine type, age, vaccine match and co-morbidity support these findings; however, dose-response results were inconsistent. Certainty in the evidence was assessed to be very low due to unexplained heterogeneity and imprecision. LIMITATIONS: The inclusion of studies with relatively small sample sizes and low event rates contributed to the imprecision of summary VE and OR estimates, which were based on unadjusted data. CONCLUSION: Available evidence does not support a reduction in VE with consecutive influenza vaccination, but the possibility of reduced effectiveness cannot be ruled out due to very low certainty in this evidence. FUNDING SOURCE: CIHR Foundation Grant (PROSPERO: CRD42017059893).
Authors: Sara S Kim; Brendan Flannery; Ivo M Foppa; Jessie R Chung; Mary Patricia Nowalk; Richard K Zimmerman; Manjusha Gaglani; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Michael L Jackson; Lisa A Jackson; Manish Patel Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 20.999
Authors: Jeffrey C Kwong; Hannah Chung; James Kh Jung; Sarah A Buchan; Aaron Campigotto; Michael A Campitelli; Natasha S Crowcroft; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Kevin L Schwartz; Andrew Simor; Marek Smieja; George Zahariadis Journal: Euro Surveill Date: 2020-01
Authors: Natale Snape; Gary P Anderson; Louis B Irving; Andrew G Jarnicki; Aeron C Hurt; Tina Collins; Yang Xi; John W Upham Journal: NPJ Vaccines Date: 2022-01-24 Impact factor: 7.344
Authors: Janna R Shapiro; Huifen Li; Rosemary Morgan; Yiyin Chen; Helen Kuo; Xiaoxuan Ning; Patrick Shea; Cunjin Wu; Katherine Merport; Rayna Saldanha; Suifeng Liu; Engle Abrams; Yan Chen; Denise C Kelly; Eileen Sheridan-Malone; Lan Wang; Scott L Zeger; Sabra L Klein; Sean X Leng Journal: NPJ Vaccines Date: 2021-12-09 Impact factor: 7.344
Authors: Edward M Hill; Stavros Petrou; Henry Forster; Simon de Lusignan; Ivelina Yonova; Matt J Keeling Journal: PLoS Comput Biol Date: 2020-10-06 Impact factor: 4.475
Authors: Amy C Sherman; Lilin Lai; Mary Bower; Muktha S Natrajan; Christopher Huerta; Vinit Karmali; Jennifer Kleinhenz; Yongxian Xu; Nadine Rouphael; Mark J Mulligan Journal: Vaccines (Basel) Date: 2020-11-07